Pretherapeutic Heterogeneity of Somatostatin Receptor Expression in Neuroendocrine Neoplasia: An Innovative Predictor of Response to Everolimus? Abstract #2916

Introduction: In patients with bronchopulmonary or gastroenteropancreatic neuroendocrine neoplasms (NEN) the mTOR inhibitor everolimus may prolong progression-free survival (PFS). However, this is countered by potentially significant toxicity.
Aim(s): The aim of this study was to evaluate the lesional asphericity (ASP) in pre-therapeutic somatostatin receptor (SSR) imaging as the first diagnostic predictive marker for PFS.
Materials and methods: A retrospective bicentric cohort study in 30 patients (m=17, w=13, median age, 59 [38-75] years) with pre-therapeutic [111In-DTPA0]octreotide scintigraphy (Octreoscan®). The functional volumes of up to 3 leading lesions per patient (n=74) were assessed by semiautomatic, background-adapted segmentation (ROVER, version 2.1.20) and the heterogeneity of lesional SSR expression, the asphericity (ASP), was calculated. Kaplan-Meier (KM) analysis and log-rank test as well as univariate Cox regression with respect to progression-free survival (PFS) were performed for the maximum ASP measured per patient.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr. med. Christoph Wetz

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2882 Impact of Ga68-DOTATOC PET/MRI on Therapy Management in Patients with Neuroendocrine Neoplasia (NEN) - Preliminary Results
Introduction: Integrated PET/MRI combines the sensitivity and functional relevance of PET imaging and the spatial resolution and soft tissue contrast of MRI.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. med. Piotr Radojewski
#2917 Quantification of Intratherapeutic SPECT/CT for Lutetium-177-DOTATOC PRRT in Neuroendocrine Tumors
Introduction: In PRRT for NET, feasibility of lesion uptake quantification in Lu-177-DOTATOC SPECT/CT for therapy monitoring remains unclear.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Markus Galler
Authors: Galler M, Schatka I, Buch F, Bluemel S, ...
#2924 Everolimus in Patients with Advanced Neuroendocrine Neoplasia: A Real-World Study and Analysis of Long Responders
Introduction: Everolimus is a valid therapeutic option for neuroendocrine tumors (NETs); however, data regarding the long responsders in a real-world setting, outside regulatory trials, are scanty.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Maria Rinzivillo
#2893 Prediction of Survival for Gastrointestinal Neuroendocrine Tumors: A Systematic Review of Clinical Tools
Introduction: Clinical prediction tools aggregate patient and disease information to predict outcomes. Little is known about gastrointestinal neuroendocrine tumors (GI-NET) prediction tools accuracy and utility.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Julie Hallet
Authors: Hallet J, Ho G, Beyfuss K, Chan D, ...
#2700 Pancreatic Neuroendocrine Neoplasms and Liver Metastases: When Size Matters
Introduction: Small non-functioning pNENs are low grade indolent tumors, however distant metastases have also been documented in this subset of patients
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Michela Monteleone